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The Impact of Alzheimer's Disease - The Silent Killer
Abstract
With a rise in life expectancy and the lack of a specific known cause, Alzheimer's disease is preying on our
senior citizens worldwide at an alarming rate. This paper will explain what Alzheimer’s disease is medically,
treatments we have at our disposal, preventative measures, and education on the rising economic burden.
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 Alzheimer’s disease is a progressive medical disorder that affects nerve cells in areas of 
the brain responsible for memory, cognition, language, and motor activity. Neurons, or nerve 
cells, in the brain transmit signals to and from multiple areas of the brain and central nervous 
system, with a chemical called acetylcholine. Binding of acetylcholine from one neuron to 
another is the very basis of brain activity, and the neurons responsible for producing 
acetylcholine are affected by Alzheimer’s disease. As Alzheimer’s disease progresses 
acetylcholine production is reduced and neurons slowly lose function and begin to die after 
which neurons and neurotransmitters can no longer be reproduced or repaired (Alzheimer’s 
Association, 2016; National Institute on Aging, 2016; Webster’s Medical Dictionary, 2016). 
    The area in the brain responsible for memory retention is the hippocampus, and it is 
commonly the first area to be affected by Alzheimer’s disease. In a healthy brain the 
hippocampus becomes active during memory formation and retrieval.  In a brain affected by 
Alzheimer’s disease, forming new and retrieving old memories becomes increasingly more 
difficult due to the loss of acetylcholine-producing neurons in the hippocampus. As hippocampal 
neurons continue to decay, communication between nerve cells is permanently lost. Most 
commonly memory loss is one of the first observable symptoms of Alzheimer’s disease 
(Alzheimer’s Association, 2016; National Institute on Aging, 2016; Webster’s Medical 
Dictionary, 2016). 
      Multiple areas in the brain are responsible for cognition, including the frontal cortex, 
occipital lobes, and hippocampus. Cognitive abilities require communication and transfer of 
information from all of these brain regions.  Nerve cell damage in any of these areas hinders 
thinking abilities and problem-solving skills (Alzheimer’s Association, 2016; National Institute 
on Aging, 2016; Webster’s Medical Dictionary, 2016). 
1
Dailey: The Impact of Alzheimer's Disease
Published by ScholarSpace @ JCCC, 2016
 Motor activity is generated in the motor cortex, which is located in the frontal lobe. As 
neurons decay and die in the motor cortex, movement becomes increasingly difficult and 
proceeds to a total loss of mobility (National Institute on Aging, 2016). 
The Alzheimer’s foundation of America (AFA) identifies three stages of Alzheimer’s 
disease as mild, moderate, and severe. These stages reflect the movement of the disease from the 
central areas of the brain outward. As the disease progresses the symptoms become more severe 
(Alzheimer’s Foundation of America, 2016). 
     In the mild stage of Alzheimer’s disease, the hippocampus appears to be the area 
affected the most. Patients experience short-term memory loss, most often have trouble 
remembering what they were doing, saying, or where they were going.  Patients often find 
themselves more confused and find themselves struggling to remember the steps needed to 
complete a previously normal task. Complaints of memory loss are often the first indication that 
a person is suffering from Alzheimer’s disease.  Patients begin to have increased trouble 
speaking and understanding what other people are saying, this could perhaps be because of the 
inability to remember words and word meanings. Patients begin to need outside assistance. 
Family and friends will also begin to notice unexpected behaviors and personality changes 
(Alzheimer’s Association, 2016). 
     In the moderate stage of Alzheimer’s disease, patients begin to lose long-term memory 
as well as permanent loss of short term memories. The ability to learn new tasks is extremely 
limited. In this stage the areas responsible for memories of specific information such as facial 
recognition rapidly begins to decline, with intermittent bouts of lucidity. The spread of the 
disease from the central brain regions outward is now noticeable as patients begin to lose the 
ability to differentiate between and recognize family members. Processing sensory information 
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 or normal reasoning is also inhibited by the degeneration of neurons. Patients now need complete 
supervision and assistance with tasks such as washing and feeding themselves, indicating that the 
disease has now spread to the motor areas. In some cases, patients in this stage experience 
hallucinations, delusions, paranoia, and impulsivity indicating that sensory areas of the brain are 
degenerating as well (Alzheimer’s Association, 2016; Alzheimer’s Foundation of America, 
2016).  
    The severe stage of Alzheimer’s disease proceeds towards death. The extensive 
amount of degeneration of the brain’s neurons (see Fig. 1) leads to profound loss of abilities. 
Patients can no longer communicate and are completely dependent on outside care. The loss of 
motor neurons is so profound that the patient can no longer swallow or breathe on their own. The 
body completely shuts down as the brain shrinks and dies (National Institute on Aging, 2016).  
 
Figure 1    Shown here are two representation images of a healthy brain and a brain afflicted with severe  
   Alzheimer’s disease. The National Institute on Aging (2016) shows the extreme atrophy that  
   Happens in the hippocampus and cerebral cortex. With Alzheimer’s disease the brain shrinks  
   and eventually dies. 
 
 
What people do not know about Alzheimer’s disease. 
    Considerable survey research has been conducted asking people what they know about 
Alzheimer’s disease, including what people know about the disease and its symptoms. The 
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 survey asked whether people think that Alzheimer’s disease is curable, treatable, reversible or 
fatal, and also inquired about whether there was an accurate test to determine whether someone 
has the disease (Harvard School of Public Health, 2011; National Institute on Aging, 2016; 
Alzheimer’s Foundation of America, 2016).  
According to one study, the population surveyed did not seem to understand that 
Alzheimer’s disease is a serious disease. The Harvard School of Public Health (2011) completed 
a phone study asking people from five countries, one of which was the United States, to rank 
their fear of diseases, from the the most to least fearful. The list included cancer, heart disease, 
stroke, Alzheimer’s disease, diabetes, depression, and influenza. The results showed that in four 
of the five countries, cancer was the most feared disease by all participants. In those four 
countries, Alzheimer’s disease was rated the second most fearful disease by only 25% of the 
participants. Ironically, all of the diseases are curable or manageable with treatment, except 
Alzheimer’s disease, which suggests that most people have insufficient information about 
Alzheimer’s disease.  
 The Harvard School of Public Health (2011) survey included 2678 respondents, most 
reported low fear of Alzheimer’s disease. In addition, fewer than half recognized that 
Alzheimer’s is a fatal disease, when in fact Alzheimer’s if the seventh leading cause of death in 
high income countries. Alzheimer’s disease is the only cause of death among the top ten causes 
of death in the United States that cannot be clinically prevented or effectively treated. Multiple 
studies show that Alzheimer’s disease might eventually become one of the most prominent 
causes of death because of improper diagnosis, improper data collection, and lack of proper 
health insurance (National Institute on Aging, 2016).  
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     In addition to lack of fear of Alzheimer’s disease and knowledge of fatality of 
Alzheimer’s disease, respondents of the HPSH (2011) study reported that they believe there is 
now an effective medical or pharmaceutical treatment to slow the progression of Alzheimer’s 
disease. The study also shows that most people believe there is medication that will make the 
symptom of Alzheimer’s disease less severe.  
However, according to the Alzheimer’s Association (2016) there are two FDA approved 
medications-- cholinesterase inhibitors and memantine. The pharmaceutical treatments approved 
by the Food and Drug Administration in the United States only temporarily help symptoms, they 
are not effective treatments or cures (see Fig. 2). For example, 47% of respondent from the 
United States think there is an effective treatment to alleviate symptoms. 
   The current FDA approved treatments include cholinesterase inhibitors which 
temporarily help to prevent the breakdown of acetylcholine, delaying symptoms for as much as 
six to twelve months. This medication is generally prescribed in the mild to early moderate stage 
of AD. Aricept, Razadyne, and Exelon are the most common cholinesterase inhibitors prescribed 
(Alzheimer’s Association, 2016). 
     Memantine regulates the activity of glutamate, a neurotransmitter involved in learning 
and memory retention. Memantine delays the progression of symptoms for some people 
temporarily. Many experts consider its benefits similar to those of cholinesterase inhibitors. 
Nemenda is most commonly prescribed and is only approved for moderate to severe Alzheimer’s 
disease (Alzheimer’s Association, 2016). 
The Harvard School of Public Health (2011) also reported that nearly half of respondents 
believed that there was an effective test to determine if a patient is suffering from Alzheimer’s 
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 disease, for example, in the United States, 59% of respondents reported that they thought there is 
a reliable and accurate test for Alzheimer’s disease (see Fig. 2).  
Figure 2  
 
     The truth is that current medical test are ineffective in diagnosing Alzheimer’s disease. 
Neurons affected by Alzheimer’s disease start to deteriorate as much as ten to twenty years 
before symptoms begin to affect the patient. Typically, patients are diagnosed in the mild stage 
of Alzheimer’s disease, when memory problems begin. Damage to the brain areas affected by 
Alzheimer’s disease is already severe at the mild stage of the disease. Degeneration in the 
hippocampus, the frontal cortex, and occipital lobes is irreversible by this time. With no way to 
halt or reverse the decline of memory and cognitive abilities, discovering the death of 
neurotransmitters and nerve cells well before symptoms occur is necessary to alleviate symptoms 
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 and develop better treatments. Having better diagnostic tools will be the only way to enable that 
to happen (Landau, 2011). 
Current Diagnostic Methods 
    The Mayo Clinic (2016) has published a set of diagnostic tests because at this time 
there is no single medical test to determine if a person is suffering from Alzheimer’s disease. 
Diagnosis is difficult and requires extensive and careful medical evaluation. Because neurons 
affected by Alzheimer’s disease begin to decay the amount of healthy neurotransmitters as much 
as ten to twenty years before symptoms begin to affect the patient, damage is already pronounced 
at the mild stage of the disease. Typically, patients are diagnosis in the Mild stage of Alzheimer’s 
disease. Brain areas that have already deteriorated when diagnosis has been made are the 
hippocampus, the frontal cortex, and occipital lobes and at this stage of degeneration the damage 
is irreversible (Landau, 2011).   
    The Mayo Clinic tests (2016) include a thorough medical history, physical exams, and 
neurological exams. The physical tests include testing reflexes, coordination, sight and hearing, 
and muscle tone and strength. These tests determine if testing for Alzheimer’s should proceed. 
Lab tests determine that conditions such as thyroid disorders, vitamin deficiencies, and diabetes 
are not causes of memory loss and confusion. An extensive mental status assessment is 
performed to assess cognitive function.  
   The Mayo Clinic suggests the use of brain imaging such as CT scans to rule out tumors, 
strokes, and head injuries as causes for patient’s symptoms. MRI scans are used to assess if brain 
atrophy implicates Alzheimer’s disease as the cause of symptoms. Recently improved PET scans 
use glucose to show brain activity and can also show brain levels of amyloid plaques and tangles, 
two brain abnormalities associated with Alzheimer’s disease. Unfortunately, the new PET scans 
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 are not yet available to all medical doctors. Theses PET techniques are only found in research 
and clinical trial settings (Mayo Clinic, 2016).  
   Cerebrospinal fluid can be tested for biomarkers that indicate a genetic factor for early 
on-set Alzheimer’s disease (Mayo Clinic, 2016). Only a small fraction of 1% of people 
worldwide have the rare genetic form of Alzheimer’s disease, these people tend to show signs of 
amyloid plaques in PET scans and in cerebrospinal fluid tests. Another biomarker of interest is 
tau, which is implicated in the development of neurofibrillary tangles that build up in the brains 
of Alzheimer’s disease patients. Notably these tangles are found in the hippocampus or memory 
center of the brain. Tau mimics the shape of healthy cells and destroys them, however genetic 
testing for this biomarker is implausible at this time as there is no scan to detect the tau in a 
living patient (Landau, 2010). 
    Currently the diagnosis of Alzheimer’s disease is difficult because no specific cause 
has been discovered. With no specific cause identified, there are no reliable treatments to cure or 
reverse the atrophy that develops in the brain afflicted with Alzheimer’s disease. Improved 
participant numbers in research and clinical trials will lead to a far superior diagnostic system 
and an opportunity to develop sophisticated tools for earlier diagnosis. In addition to advancing 
diagnosis increased research will inevitably lead to scientific breakthroughs in the discovery of a 
cure.  
Economic Burden of Alzheimer’s Disease  
    Alzheimer’s disease will affect millions of people if adequate treatment is not 
discovered, and right now curing Alzheimer’s is not plausible in the near future. As life 
expectancy increases worldwide, the number of aging adults has exponentially risen. With the 
increase of the aged population, the prevalence of Alzheimer’s disease is aggressively rising, 
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 along with a parallel increase in the economic burden of caring for a populace with a chronic 
incurable disease. In the United States alone we are spending over $200 billion dollars each year 
to treat AD patients, with Medicare shouldering the majority of the cost. Chronic disease in our 
aging population could bankrupt Medicare (National Institute on Aging, 2016). The global 
economic effect could be devastating. Multiple studies on the financial impact of Alzheimer’s 
disease are anticipating one out of 85 people will suffer from Alzheimer’s disease worldwide by 
the year 2050. Caring for AD patients in that magnitude is expected to cost billions, if not 
trillions, of dollars. (Brookmeyer, Johnson, Zeigler-Graham & Arrighi, 2007; Brookmeyer, Grey 
& Kawas, 1998; Rocca et al. 2011).  
     The annual economic cost of Alzheimer’s disease in the United States for lost wages 
is between 80-100 billion dollars, costing America $236 billion dollars yearly. Alzheimer’s 
disease is the third largest and costly disease after cancer and heart disease. With lack of proper 
patient care, exorbitant institutional care, and financial burden on caregivers, this number will 
only increase. More than 15 million caregivers provide an average of 18 billion hours of unpaid 
care, and the immediate financial burdens falls heavily on single income family members. 
Beyond the obvious financial burdens, care contributors lose over $15,000 in annual income as a 
result of reducing or quitting work to meet the demands of caregiving. The Alzheimer’s 
Association (2016) commissioned a nationwide scientific survey of more than 3,500 Americans 
and reported that “[a]larmingly, the survey revealed that many care contributors had to cut back 
on basic necessities such as food and medical care for themselves and their families. They are 28 
percent more likely than other adults to eat less or go hungry because they cannot afford to pay 
for food” (Alzheimer’s Association, 2016, p. 6). 
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     When stacked financially against the annual cost of caring for cancer and heart disease, 
Alzheimer’s is a major contender in the economic health crisis.  The agency for Healthcare 
Research and Quality (AHRQ) estimates that the direct medical cost (total of all health care cost) 
for cancer in the United States annually is $895 billion dollars and the estimate for heart disease 
is $753 billion dollars (Agency for Healthcare Research and Quality, 2016).  
Prevention 
     With the list of chronic diseases growing and the shortage of funding for research 
being stretched, the major focus today seems to be preventing Alzheimer’s disease (Pope, Shue, 
& Beck, 2003). Focusing on prevention at an early age could reduce risk factors by as much as 
25-45%. Reducing the risk of factors believed to be correlated with AD, such as heart disease, 
high blood pressure, diabetes, obesity, and depression may lead to a decreased risk of developing 
late on-set Alzheimer’s disease, and reduce risk of developing the related diseases as well (Pope, 
Shue, & Beck, 2003).  
    Ongoing research is needed to directly relate the correlation between those diseases 
and Alzheimer’s disease. Cognitive abilities decline naturally with age, and when compounded 
with Alzheimer’s disease atrophy and unstable molecules or free radical production is rapid. 
Loss of connection between neurons creates a permanent loss of communication between the 
areas of the brain, such as the frontal cortex, the hippocampus, the motor cortex and the sensory 
cortex. Without these neurons the brain will no longer communicate with body’s muscles and 
organs. Research indicates that there are no straightforward answers on how to prevent 
Alzheimer’s disease. Multiple studies have shown that a multifaceted prevention plan can reduce 
the risk factors in developing Alzheimer’s disease (Brookmeyer, Grey, & Kawas, 1998; Landau, 
2011; Pope, Shue, & Beck, 2003).    
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     Facets of healthy lifestyles begin with proper eating habits, physical activity, and 
mental and social activity. Diets high in fat, saturated fat, and cholesterol have been linked to 
incidental dementia, but diets rich in Omega-3 fatty acids and fish will lower total fat and total 
cholesterol and will assist in reducing the risk. Healthy diets also reduce risk of Type 2 diabetes, 
high blood pressure, heart disease, and obesity -- all diseases correlated with developing 
Alzheimer’s disease (Pope, Shue, & Beck, 2003; Bassil, & Grossberg, 2010.  
    Low levels of physical activity is a risk factor in Alzheimer’s disease. Several large 
studies show that higher physical activity increases life expectancy by two to five years. 
Increased physical activity reduces the risk of numerous chronic diseases including heart disease, 
stroke, breast cancer and colon cancer. When patients develop habits that include physical 
activity such as hiking or running they are less likely to suffer cognitive impairment (Pope, Shue, 
& Beck, 2003). 
   Continued education and cognitive activity through old age can help prolong patients’ 
cognitive abilities and delay the presentation of Alzheimer’s disease’s effects on memory and 
cognitive function (Bassil, & Grossberg, 2010). Cognitive improvements can increase quality of 
life and lower risks of depression. The Cognitive decline that can happen naturally is slightly 
deterred by an increase in stimulation in the areas of the hippocampus and cerebral cortex (Stern, 
2006). 
     According to Pope, Shue and Beck (2003), “Stress management has received little 
attention as a risk factor for Alzheimer’s disease […]” (p. 124) Chronic stress may be a risk 
factor for cognitive decline in Alzheimer’s disease. High cortisol, over-responding 
neuroendocrine and immune systems, and stress induced hormone levels can all lead to 
hippocampal damage. Reducing chronic stress will help improve quality of life and reduce the 
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 risk factor of chronic disease such as obesity, depression, high blood pressure and hypertension 
(Pope, Shue, & Beck, 2003)  
 There are no clinically proven prevention measures at this time. However, 
including any of the above mentioned prevention methods will decrease the risk of developing 
any of the correlating diseases’ and improve the quality of life in the patient. Healthy habits 
adopted early will have a positive effect in all areas of the brain, that Alzheimer’s disease 
attacks.  
Conclusion 
         More research is needed to determine if the prevention methods recommended are 
in fact plausible preventive measures. Until an empirical cure has been discovered or superior 
diagnostic system and treatments are in place, prevention is the only tool to combat Alzheimer’s 
disease and effects on the aging populace. Raising awareness of the disease can help people 
change behaviors that can prevent and delay the disease. Raising awareness will also increase the 
probability that the disease will get the attention it deserves to develop effective diagnoses and 
treatments. Raising awareness will ultimately lead to research to find a cure for Alzheimer’s 
disease—the Silent Killer.  
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